MedPath

Nitazoxanide

Generic Name
Nitazoxanide
Brand Names
Alinia, Busulfex
Drug Type
Small Molecule
Chemical Formula
C12H9N3O5S
CAS Number
55981-09-4
Unique Ingredient Identifier
SOA12P041N
Background

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .

Indication

用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions
Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia

ANI Pharmaceuticals Launches Prucalopride Tablets for Chronic Idiopathic Constipation with 180-Day Exclusivity

• ANI Pharmaceuticals has launched Prucalopride Tablets, a generic version of Motegrity, after receiving FDA approval and a Competitive Generic Therapy (CGT) designation. • Prucalopride, a selective 5-HT4 receptor agonist, enhances colon muscle movement to alleviate infrequent bowel movements in adults with chronic idiopathic constipation. • Clinical trials have demonstrated prucalopride's efficacy and safety in treating chronic constipation, showing a higher proportion of patients achieving at least 3 spontaneous bowel movements per week compared to placebo. • Real-world studies suggest prucalopride has higher treatment persistence and adherence compared to other prescription medications for chronic idiopathic constipation.

GENFIT to Initiate New ACLF Clinical Trials and Awaits Key Data Readouts in 2025

• GENFIT plans to launch two new clinical trials in Q1 2025 focusing on Acute-on-Chronic Liver Failure (ACLF) with VS-01 and a new formulation of NTZ. • The trials will include patients with acute decompensation at high risk of progressing to ACLF, aiming to streamline trial execution and patient recruitment. • GENFIT anticipates data readouts from four clinical trials by the end of 2025, including the UNVEIL-IT Phase 2 trial and a Phase 1b trial for GNS561 in cholangiocarcinoma. • Strategic insights from real-world evidence and collaborations with experts have informed the trial designs, broadening inclusion criteria to address the ACLF continuum.

GENFIT Highlights Progress in PBC and ACLF Programs at The Liver Meeting 2024

• GENFIT's partner Ipsen is making strides with Iqirvo® (elafibranor) for PBC, with encouraging U.S. launch feedback and European reimbursement approvals. • GENFIT is advancing its ACLF franchise, presenting preclinical data at The Liver Meeting and planning multiple clinical studies in 2025. • The Phase 2 UNVEIL-IT trial results for VS-01 in ACLF are now expected in the second half of 2025 due to protocol modifications to improve recruitment. • New data on NIS2+® efficacy as a monitoring tool for patients with MASH will be presented at The Liver Meeting 2024.
© Copyright 2025. All Rights Reserved by MedPath